Immix Biopharma (IMMX) Change in Cash (2021 - 2026)

Immix Biopharma has disclosed Change in Cash across 6 years of filings, most recently posting -$14.7 million for Q1 2026.

• Change in Cash for Q1 2026 came in at -$14.7 million, down 733.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.3 million (up 572.67% YoY), and the FY2025 annual result was $76.2 million, up 44187.46% from the prior year.
• Change in Cash came in at -$14.7 million for Q1 2026 at Immix Biopharma, down from $78.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $78.0 million in Q4 2025 to a low of -$14.7 million in Q1 2026.
• The 5-year median for Change in Cash is -$1.8 million (2025), against an average of $3.6 million.
• Across the five-year window, Change in Cash plunged 1946.43% in 2022 and jumped 3982.61% in 2025, its largest moves.
• Immix Biopharma's Change in Cash stood at -$3.5 million in 2022, then soared by 40.44% to -$2.1 million in 2023, then advanced by 3.1% to -$2.0 million in 2024, then surged by 3982.61% to $78.0 million in 2025, then slumped by 118.82% to -$14.7 million in 2026.
• The last three Change in Cash figures came in at -$14.7 million (Q1 2026), $78.0 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.